Mirvetuximab soravtansine治疗卵巢癌研究进展  

Research Progress of Mirvetuximab Soravtansine in the Treatment of Ovarian Cancer

作　　者：霍丽曼 冯锐[1] 周梅 范元春[1] 孙晓利[1] HUO Liman;FENG Rui;ZHOU Mei;FAN Yuanchun;SUN Xiaoli(The Fourth Hospital of Hebei Medical University,Shijiazhuang,Hebei,China 050011)

机构地区：[1]河北医科大学第四医院,河北石家庄050011

出　　处：《中国药业》2025年第2期I0001-I0004,共4页China Pharmaceuticals

基　　金：河北省药学会医院药学科研项目[2022-Hbsyxhms-15]。

摘　　要：目的 为临床合理使用Mirvetuximab soravtansine(MIRV)提供参考。方法 采用计算机检索ClinicalTrials. gov、PubMed等数据库自建库起至2023年12月1日MIRV药物临床试验共21篇,筛选治疗卵巢癌相关的药物临床试验共12篇,其中6篇为叶酸受体α(FRα)阳性铂耐药复发性卵巢癌。总结药物临床试验中的数据、药物代谢动力学特征、临床疗效及不良反应发生情况。结果与结论 现有文献支持MIRV对FRα阳性铂耐药复发性卵巢癌的治疗,大量药物临床试验证实其可用于成人卵巢癌、FRα阳性铂耐药上皮性卵巢癌、铂耐药卵巢癌的治疗。MIRV单药或联合贝伐珠单抗已成为FRα阳性耐药复发性卵巢癌的重要治疗药物。在治疗过程中,MIRV安全性较好,不良反应总体可控。但MIRV相关安全性及有效性数据尚不充分,还有待开展更大规模的研究深入观察。Objective To provide a reference for the rational clinical use of Mirvetuximab soravtansine(MIRV).Methods A total of 21 MIRV clinical trials in the ClinicalTrials.gov and PubMed from the inception of each database to December 1,2023 were searched,12 drug clinical trials related to the treatment of ovarian cancer were screened,including six for folate receptorα(FRα)-positive platinum-resistant recurrent ovarian cancer(PROC).The clinical data,pharmacokinetic characteristics,clinical efficacy and incidence of adverse reactions in drug clinical trials were summarized.Results and Conclusion Existing literature supports MIRV in the treatment of FRα-positive PROC,and numerous clinical trials have confirmed its efficacy in treating adult ovarian cancer,FRα-positive platinum-resistant epithelial ovarian cancer,and platinum-resistant ovarian cancer.MIRV monotherapy or combination with bevacizumab has become an important therapeutic drug for FRα-positive PROC.MIRV is safe and overall adverse reactions are tolerable during the treatment,while the relevant safety and efficacy data are not yet sufficient,and further large-scale research is needed.

关 键 词：Mirvetuximab soravtansine 抗体-药物结合物 叶酸受体Α 卵巢癌 药物临床研究 

分 类 号：R965[医药卫生—药理学]